Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.


Life Science
Our Mission is to enable prediction, monitoring, diagnosis & successful drug development for Alzheimer’s disease.

Diadem is developing the first blood-based prognostic test for the early detection of dementia, with a focus on Alzheimer’s disease.

The lack of accurate, accessible and affordable diagnostic tools is a major contributor to the absence of effective treatments for this devastating condition. As a result, patients are not diagnosed until late in the illness, when effective treatment is no longer possible.

Diadem’s and predictive blood-based prognostic test for the first time makes it possible to diagnose patients early in the disease process, when effective interventions and better outcomes are far more feasible. The utility of the approach has been demonstrated in early clinical studies. Additional retrospective and prospective clinical trials are planned to further validate clinical claims and support widespread adoption and use worldwide.


Gerald Möller
Chairman of the Board of Diadem

Diadem’s minimally invasive technology for the early diagnosis of Alzheimer’s disease has enormous potential to transform the treatment of dementia and help spur the availability of effective new therapies.

About Alzheimer’s Disease


There are about 50 million people suffering from dementia worldwide. Alzheimer’s disease is the most common form and accounts for 60-70% of cases. At present there are no disease modifying treatments for Alzheimer's, and therapies to treat symptoms are limited.


Diadem was founded in 2012 as a spin-off of the University of Brescia (Italy). Its founding and lead investor is Milan-based Panakes Partners, a venture capital firm that finances promising high potential biomedical companies in Europe and Israel.

Paul Kinnon
CEO @ Diadem

Diadem’s transformational technology for the first time makes it possible to diagnose Alzheimer’s early in the disease process and to predict whether the disease will progress. This will allow patients to seek treatment at a time when it is still possible to impact disease progression and preserve function.

​​​​Diadem is preparing for rapid commercialisation of its initial Alzheimer’s prognostic via a global launch in collaboration with strategic partners, targeted for 2021.